{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-100780","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2023-09-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.977910+00:00","generated_at":"2026-06-10T17:42:43.762316+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"NRx names Richard Narido interim CFO; Seth Van Voorhees resigns Sept 30","bullets":["Seth Van Voorhees resigned as CFO effective Sept 30, 2023, no disagreement cited.","Richard Narido appointed interim CFO effective Sept 13, 2023, via LifeSci Advisors consulting agreement.","Narido previously CFO of Lucira Health until Pfizer acquisition in April 2023.","LifeSci Agreement term is two years; includes non-competition/non-solicitation and placement fee provisions.","Agreement prohibits solicitation of LifeSci-introduced professionals for one year, with 15% placement fee."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-100780","json":"https://secwatch.observer/filing/0001104659-23-100780.json","markdown":"https://secwatch.observer/filing/0001104659-23-100780.md","text":"https://secwatch.observer/filing/0001104659-23-100780.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923100780/0001104659-23-100780-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923100780/tm2317653d13_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T17:42:43.762316+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"280116a31c","claim":"Seth Van Voorhees resigned as Chief Financial Officer at NRX Pharmaceuticals, Inc..","evidence_excerpt":"On September 11, 2023, Seth Van Voorhees, Ph.D., resigned from his position as the Chief Financial Officer of the Company. His resignation will be effective as of September 30, 2023, in order to facilitate a smooth transition.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923100780/0001104659-23-100780-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Financial Officer"}],"fact_type":"executive_change"},{"claim_id":"51c9d03db2","claim":"Richard Narido was appointed as Interim Chief Financial Officer at NRX Pharmaceuticals, Inc..","evidence_excerpt":"on September 13, 2023, the Company appointed Richard Narido, 45, to serve as Interim Chief Financial Officer of the Company.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000110465923100780/0001104659-23-100780-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim Chief Financial Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}